Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty
1129-ER-050
1129-ER-01M
Best Seller
Graph showing dose-dependent bioactivity of human ErbB2 / Her2 protein
2 Images
Product Details
Citations (54)
FAQs
Supplemental Products
Reviews (10)

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF Summary

Product Specifications

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to block anti-ErbB2 mediated inhibition of SK‑BR‑3 human breast cancer cell proliferation. Brodowicz, T. et al. (1997) Int. J. Cancer 73:875. The ED50 for this effect is 0.3-1.2 μg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 Monoclonal Antibody (Trastuzumab, Catalog # MAB9589).
Source
Mouse myeloma cell line, NS0-derived human ErbB2/Her2 protein
Human Erb B2
(Thr23-Thr652)
Accession # NP_004439
IEGRMD Human IgG1
(Pro100-Lys330)
6 His-tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Thr23
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
96.8 kDa (monomer)
SDS-PAGE
125-130 kDa, reducing conditions
220-250 kDa, non-reducing conditions

Product Datasheets

You must select a language.

x

1129-ER

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1129-ER

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

SDS-PAGE Graph showing dose-dependent bioactivity of human ErbB2 / Her2 protein View Larger

1 μg/lane of Recombinant Human ErbB2 Fc Chimera was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing major bands at 125-130 kDa and 220-250 kDa, respectively.

Bioactivity Graph showing dose-dependent bioactivity of human ErbB2 / Her2 protein View Larger

Recombinant human ErB2 / Her2 (1129-ER) blocks anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer proliferation. The ED50 for this effect is 0.3-1.2 µg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 Monoclonal Antibody (Trastuzumab, MAB9589).

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: ErbB2/Her2

ErbB2, also called Neu and Her2 (human epidermal growth factor receptor 2), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB2 is widely expressed in epithelial cells and has also been found to be over-expressed in a large number of breast carcinomas. Among ErbB family members, ErbB2 is unique in that it has no identified ligands. Rather, ErbB2 heterodimerizes with the other members of the ErbB family (ErbB1 (EGFR), ErbB3, ErbB4) to form higher affinity signaling complexes. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. Interestingly, this same three amino acid signal has also been found in ErbB1 and ErbB4. Phosphoinositide 3-kinase has been shown to play a role in ErbB2 signal transduction. The cytoplasmic domain of ErbB2 has been shown to associate with beta-catenin and plakoglobin. Human ErbB2 consists of 1255 amino acids (aa) with a 21 aa signal sequence, a 631 aa extracellular domain, a 23 aa transmembrane region, and a 580 aa cytoplasmic domain. ErbB2 can be shed from the cell surface by proteolytic cleavage by an unidentified protease. ErbB2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation (1-10).

References
  1. Coussens, L. et. al. (1985) Science 230:1132.
  2. Yamamoto, T. et. al. (1986) Nature 319:230.
  3. Kanai, Y. et. al. (1995) Biochem. Biophys. Res. Commun. 208:1067.
  4. Codony-Servat, J. et. al. (1999) Cancer Res. 59:1196.
  5. Carraway, K.L. 3rd et. al.  (1994) J. Biol. Chem. 269:14303.
  6. Emkey, R. and C.R. Kahn (1997) J. Biol. Chem. 272:31172.
  7. Schaefer, G. et. al. (1999) J. Biol. Chem. 274:859.
  8. Schlessinger, J. (2000) Cell 103:211.
  9. Hellyer, N.J. et. al. (2001) J. Biol. Chem. 276:42153.
  10. Daly, R.J. (1999) Growth Factors 16:255.
Long Name
Receptor Tyrosine Protein Kinase ErbB2
Entrez Gene IDs
2064 (Human); 13866 (Mouse); 24337 (Rat); 102146608 (Cynomolgus Monkey)
Alternate Names
CD340 antigen; CD340; c-erb B2/neu protein; EC 2.7.10; EGFR2; ErbB2; HER2; HER-2; HER2EC 2.7.10.1; herstatin; Metastatic lymph node gene 19 protein; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; neuroblastoma/glioblastoma derived oncogene homolog; NGL; NGLTKR1; p185erbB2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog); v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian)

Citations for Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

54 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Enhancement of in vivo targeting properties of ErbB2 aptamer by chemical modification
    Authors: Park, JY;Cho, YL;Chae, JR;Lee, JH;Kang, WJ;
    PloS one
    Species: N/A
    Sample Types: N/A
    Applications: Bioassay
  2. The Significance of Cell Surface N-Glycosylation for Internalization and Potency of Cytotoxic Conjugates Targeting Receptor Tyrosine Kinases
    Authors: M Po?niak, D ?ukowska, A G?daj, MA Krzy?cik, N Por?bska, M Zakrzewska, J Otlewski, ? Opali?ski
    International Journal of Molecular Sciences, 2022-07-31;23(15):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
    Authors: N Hebbar, R Epperly, A Vaidya, U Thanekar, SE Moore, M Umeda, J Ma, SL Patil, D Langfitt, S Huang, C Cheng, JM Klco, S Gottschalk, MP Velasquez
    Nature Communications, 2022-01-31;13(1):587.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  4. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis
    Authors: N Stoup, M Liberelle, C Schulz, S Cavdarli, R Vasseur, R Magnez, F Lahdaoui, N Skrypek, F Peretti, F Frénois, X Thuru, P Melnyk, N Renault, N Jonckheere, N Lebègue, I Van Seunin
    Cancers, 2021-11-16;13(22):.
    Species: Human
    Sample Types: Recombinant Proteins
    Applications: Bioassay
  5. Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein
    Authors: J Garousi, H Ding, E von Wittin, T Xu, A Vorobyeva, M Oroujeni, A Orlova, S Hober, T Gräslund, V Tolmachev
    Pharmaceutics, 2021-11-03;13(11):.
    Species: Human
    Sample Types: Recombinant Proteins
    Applications: Bioassay
  6. A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy
    Authors: R Chidiac, M Abedin, G Macleod, A Yang, PE Thibeault, LL Blazer, JJ Adams, L Zhang, H Roehrich, HN Jo, S Seshagiri, SS Sidhu, HJ Junge, S Angers
    Embo Molecular Medicine, 2021-06-09;0(0):e13977.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  7. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
    Authors: H Ding, T Xu, J Zhang, V Tolmachev, M Oroujeni, A Orlova, T Gräslund, A Vorobyeva
    Pharmaceutics, 2021-03-23;13(3):.
    Species: Human
    Sample Types: Protein
    Applications: Surface Plasmon Resonance
  8. Bioproduced Proteins On Demand (Bio-POD) in hydrogels using Pichia pastoris
    Authors: SF Yuan, SM Brooks, AW Nguyen, WL Lin, TG Johnston, JA Maynard, A Nelson, HS Alper
    Bioactive materials, 2021-01-27;6(8):2390-2399.
    Species: Hamster
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
    Authors: T Xu, H Ding, A Vorobyeva, M Oroujeni, A Orlova, V Tolmachev, T Gräslund
    Cancers, 2020-12-30;13(1):.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  10. Antibody-like proteins that capture and neutralize SARS-CoV-2
    Authors: T Kondo, Y Iwatani, K Matsuoka, T Fujino, S Umemoto, Y Yokomaku, K Ishizaki, S Kito, T Sezaki, G Hayashi, H Murakami
    Sci Adv, 2020-10-14;0(0):.
    Species: Human
    Sample Types: Antibody
    Applications: Bioassay
  11. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices
    Authors: S Dengl, K Mayer, F Bormann, H Duerr, E Hoffmann, B Nussbaum, M Tischler, M Wagner, A Kuglstatte, L Leibrock, C Buldun, G Georges, U Brinkmann
    Nat Commun, 2020-10-02;11(1):4974.
    Species: N/A
    Sample Types: Small Molecule
    Applications: ELISA Capture
  12. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
    Authors: AK Wege, N Kirchhamme, LV Kazandjian, S Prassl, M Brandt, G Piendl, O Ortmann, S Fischer, G Brockhoff
    J Transl Med, 2020-08-15;18(1):316.
    Species: Human
    Sample Types: Protein, Whole Cells
    Applications: Bioassay, ELISA Capture
  13. Targeting hydrogen sulphide signaling in breast cancer
    Authors: RA Youness, AZ Gad, K Sanber, YJ Ahn, GJ Lee, E Khallaf, HM Hafez, AA Motaal, N Ahmed, MZ Gad
    Journal of advanced research, 2020-07-16;27(0):177-190.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
    Authors: M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai, TT Byrd, J Hicks, ML Xu, C Gerken, M Kalra, C Robertson, H Zhang, A Shree, B Mehta, O Dakhova, VS Salsman, B Grilley, A Gee, G Dotti, HE Heslop, MK Brenner, WS Wels, S Gottschalk, N Ahmed
    Nat Commun, 2020-07-15;11(1):3549.
    Species: Human
    Sample Types: Whole Cells
    Applications: CAR-T (Flow Cytometry)
  15. Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases
    Authors: Z Dai, XN Zhang, F Nasertorab, Q Cheng, J Li, BB Katz, G Smbatyan, H Pei, SG Louie, HJ Lenz, RC Stevens, Y Zhang
    Sci Adv, 2020-06-03;6(23):eaba6752.
    Species: Human
    Sample Types: Protein
    Applications: ELISA Capture
  16. Reshaping Nanobodies for affinity purification on protein A
    Authors: M Crauwels, N Van Vaeren, B Kulaya Nee, C Vincke, M D'Huyvette, N Devoogdt, S Muylderman, C Xavier
    N Biotechnol, 2020-01-27;0(0):.
    Species: Human
    Sample Types: Protein
    Applications: Surface Plasmon Resonance (SPR
  17. Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
    Authors: CL Parker, TM Jacobs, JT Huckaby, D Harit, SK Lai
    MBio, 2020-01-21;11(1):.
    Species: Human
    Sample Types:
    Applications: ELISA (Capture)
  18. Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
    Authors: T Kadonosono, W Yimchuen, Y Ota, K See, T Furuta, T Shiozawa, M Kitazawa, Y Goto, A Patil, T Kuchimaru, S Kizaka-Kon
    Sci Rep, 2020-01-21;10(1):891.
    Species: Human
    Sample Types: Protein
    Applications: Direct ELISA
  19. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis
    Authors: M Liberelle, R Magnez, X Thuru, Y Bencheikh, S Ravez, C Quenon, AS Drucbert, C Foulon, P Melnyk, IV Seuningen, N Lebègue
    Sci Rep, 2019-11-13;9(1):16678.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
    Authors: J Medina-Ech, M Hinterberg, M Testori, M Geiger, R Giessel, B Bathke, R Kassub, F Gräbnitz, G Fiore, ST Wennier, P Chaplin, M Suter, H Hochrein, H Lauterbach
    Nat Commun, 2019-11-06;10(1):5041.
    Species: Mouse
    Sample Types: Serum
    Applications: ELISA Capture
  21. Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies
    Authors: S Ahn, J Li, C Sun, K Gao, K Hirabayash, H Li, B Savoldo, R Liu, G Dotti
    Cancer Immunol Res, 2019-03-06;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: CAR-T (Bioassay)
  22. Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2
    Authors: SJ Tobin, DL Wakefield, V Jones, X Liu, D Schmolze, T Jovanovi?-
    Sci Rep, 2018-10-11;8(1):15154.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  23. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
    Authors: CW Helsen, JA Hammill, VWC Lau, KA Mwawasi, A Afsahi, K Bezverbnay, L Newhook, DL Hayes, C Aarts, B Bojovic, GF Denisova, JM Kwiecien, I Brain, H Derocher, K Milne, BH Nelson, JL Bramson
    Nat Commun, 2018-08-03;9(1):3049.
    Species: Human
    Sample Types: Whole Cells
    Applications: CAR-T (Flow Cytometry)
  24. d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution
    Authors: M Pruszynski, CM Kang, E Koumariano, G Vaidyanath, MR Zalutsky
    Molecules, 2018-05-20;23(5):.
    Applications: Bioassay
  25. Molecular design of radiocopper-labelled Affibody molecules
    Authors: V Tolmachev, TJ Grönroos, CB Yim, J Garousi, Y Yue, S Grimm, J Rajander, A Perols, M Haaparanta, O Solin, R Ferdani, A Orlova, CJ Anderson, AE Karlström
    Sci Rep, 2018-04-25;8(1):6542.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  26. Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts
    Authors: M Kahl, F Settele, P Knick, U Haupts, E Bosse-Doen
    Protein Expr. Purif., 2018-04-25;0(0):.
    Applications: Bioassay
  27. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Authors: Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N
    Neuro Oncol, 2018-03-27;20(4):506-518.
    Species: Human
    Sample Types: Whole Cells
    Applications: CAR-T (Bioassay)
  28. Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells
    Authors: I Correa, KM Ilieva, S Crescioli, S Lombardi, M Figini, A Cheung, JF Spicer, ANJ Tutt, FO Nestle, P Karagianni, KE Lacy, SN Karagianni
    Front Immunol, 2018-03-23;9(0):493.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  29. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses
    Authors: J Lee, HA Kang, JS Bae, KD Kim, KH Lee, KJ Lim, MJ Choo, SJ Chang
    MAbs, 2018-03-14;0(0):1-102.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: ELISA Capture
  30. Identification of high affinity HER2 binding antibodies using CHO Fab surface display
    Authors: AW Nguyen, KC Le, JA Maynard
    Protein Eng. Des. Sel., 2018-03-01;31(3):91-101.
    Species: Human
    Sample Types: Recombinant Protein, Whole Cells
    Applications: ELISA Capture, Flow Cytometry, ICC
  31. Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities
    Authors: N Shinozaki, R Hashimoto, K Fukui, S Uchiyama
    Sci Rep, 2017-07-19;7(1):5794.
    Applications: Bioassay
  32. Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
    Authors: B Petrovic, T Gianni, V Gatta, G Campadelli
    PLoS Pathog., 2017-04-19;13(4):e1006352.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  33. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide
    Authors: J Tobias, J Jasinska, K Baier, M Kundi, N Ede, C Zielinski, U Wiedermann
    BMC Cancer, 2017-02-09;17(1):118.
    Species: Mouse
    Sample Types: Serum
    Applications: Bioassay
  34. A Highly Diverse and Functional Na�ve Ubiquitin Variant Library for Generation of Intracellular Affinity Reagents
    Authors: Sachdev S Sidhu
    J. Mol. Biol., 2016-11-22;0(0):.
    Species: Human
    Sample Types: Protein
    Applications: Direct ELISA, Western Blot
  35. Salt Effect Accelerates Site-Selective Cysteine Bioconjugation
    Authors: Peng Dai
    ACS Cent Sci, 2016-08-25;2(9):637-646.
    Applications: Bioassay
  36. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape.
    Authors: Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S, Wakefield A, Fousek K, Bielamowicz K, Chow K, Brawley V, Byrd T, Krebs S, Gottschalk S, Wels W, Baker M, Dotti G, Mamonkin M, Brenner M, Orange J, Ahmed N
    J Clin Invest, 2016-07-18;126(8):3036-52.
    Species: Human
    Sample Types: Whole Cells
    Applications: CAR-T (Bioassay), CAR-T (Flow Cytometry)
  37. Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen
    Authors: F Selis, G Focà, A Sandomenic, C Marra, C Di Mauro, G Saccani Jo, S Scaramuzza, A Politano, R Sanna, M Ruvo, G Tonon
    Int J Mol Sci, 2016-04-01;17(4):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: ELISA (Capture)
  38. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.
    Authors: Kanojia D, Balyasnikova I, Morshed R, Frank R, Yu D, Zhang L, Spencer D, Kim J, Han Y, Yu D, Ahmed A, Aboody K, Lesniak M
    Stem Cells, 2015-08-11;33(10):2985-94.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Bioassay
  39. A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis.
    Authors: Leung K, Batey S, Rowlands R, Isaac S, Jones P, Drewett V, Carvalho J, Gaspar M, Weller S, Medcalf M, Wydro M, Pegram R, Mudde G, Bauer A, Moulder K, Woisetschlager M, Tuna M, Haurum J, Sun H
    Mol Ther, 2015-08-03;23(11):1722-33.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  40. Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.
    Authors: Zhou Q, Uhlig K, Muth A, Kimpel J, Levy C, Munch R, Seifried J, Pfeiffer A, Trkola A, Coulibaly C, von Laer D, Wels W, Hartwig U, Verhoeyen E, Buchholz C
    J Immunol, 2015-07-31;195(5):2493-501.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  41. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
    Authors: VanSeggelen H, Hammill J, Dvorkin-Gheva A, Tantalo D, Kwiecien J, Denisova G, Rabinovich B, Wan Y, Bramson J
    Mol Ther, 2015-06-30;23(10):1600-10.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  42. The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines.
    Authors: Lin C, Pan I, Li Y, Pan Y, Lin M, Lu Y, Wu H, Chu C
    PLoS ONE, 2015-02-27;10(2):e0116191.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  43. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
    Authors: Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bonig H, Kohl U, Kloess S, Kohler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kuhlcke K, Seifried E, Klingemann H, Rieger M, Tonn T, Grez M, Wels W
    Mol Ther, 2014-11-06;23(2):330-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  44. Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin.
    Authors: Nilvebrant J, Astrand M, Georgieva-Kotseva M, Bjornmalm M, Lofblom J, Hober S
    PLoS ONE, 2014-08-04;9(8):e103094.
    Species: Human
    Sample Types: Protein, Virus
    Applications: Bioassay, Surface Plasmon Resonance
  45. Quantity and accessibility for specific targeting of receptors in tumours.
    Authors: Hussain, Sajid, Rodriguez-Fernandez, Maria, Braun, Gary B, Doyle, Francis, Ruoslahti, Erkki
    Sci Rep, 2014-06-10;4(0):5232.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  46. Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig) proteins with unique activities.
    Authors: Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, Ghayur T, Gu J
    PLoS ONE, 2014-05-13;9(5):e97292.
    Species: Human
    Sample Types:
    Applications: Bioassay
  47. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Authors: Kang, Jeffrey, Poovassery, Jayakuma, Bansal, Pankaj, You, Sungyong, Manjarres, Isabel M, Ober, Raimund, Ward, E Sally
    MAbs, 2013-12-26;6(2):340-53.
    Applications: Bioassay
  48. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
    Authors: Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, Zhang Y, Baskin D, Merchant F, Brawley V, Byrd T, Krebs S, Wu M, Liu H, Heslop H, Gottschalk S, Yvon E, Ahmed N
    Mol Ther, 2013-08-13;21(11):2087-101.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  49. An automated immunoassay for early specificity profiling of antibodies.
    Authors: Frese, Katrin, Eisenmann, Meike, Ostendorp, Ralf, Brocks, Bodo, Pabst, Stefan
    MAbs, 2013-02-14;5(2):279-87.
    Species: Human
    Sample Types: Antibody
    Applications: Bioassay
  50. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.
    Authors: Axup, Jun Y, Bajjuri, Krishna, Ritland, Melissa, Hutchins, Benjamin, Kim, Chan Hyu, Kazane, Stephani, Halder, Rajkumar, Forsyth, Jane S, Santidrian, Antonio, Stafin, Karin, Lu, Yingchun, Tran, Hon, Seller, Aaron J, Biroc, Sandra L, Szydlik, Aga, Pinkstaff, Jason K, Tian, Feng, Sinha, Subhash, Felding-Habermann, Brunhild, Smider, Vaughn V, Schultz, Peter G
    Proc Natl Acad Sci U S A, 2012-09-17;109(40):16101-6.
    Applications: Bioassay
  51. Design of an optimized scaffold for affibody molecules.
    Authors: Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjoberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Hoiden-Guthenberg I, Galli J, Jonasson P, Abrahmsen L
    J. Mol. Biol., 2010-03-10;398(2):232-47.
    Applications: Bioassay, Dot Blot
  52. The BMP-binding protein Crossveinless 2 is a short-range, concentration-dependent, biphasic modulator of BMP signaling in Drosophila.
    Authors: Serpe M, Umulis D, Ralston A, Chen J, Olson DJ, Avanesov A, Othmer H, O'Connor MB, Blair SS
    Dev. Cell, 2008-06-01;14(6):940-53.
    Species: Drosophila
    Sample Types: Protein
    Applications: Bioassay
  53. Development and validation of sandwich ELISA microarrays with minimal assay interference.
    Authors: Gonzalez RM, Seurynck-Servoss SL, Crowley SA
    J. Proteome Res., 2008-04-19;7(6):2406-14.
    Applications: ELISA (Standard)
  54. Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
    Authors: Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S
    Cancer Res., 2007-06-15;67(12):5957-64.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF

Average Rating: 4.9 (Based on 10 Reviews)

5 Star
90%
4 Star
10%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Marina Theodorou on 05/20/2021
Application: Binding assay/Protein-protein interaction

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Jenna Nguyen on 02/08/2019
Application: Media additive for protein or antibody production

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Jenna Nguyen on 01/30/2019
Application: Enzymatic activity in vitro

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Jenna Nguyen on 12/06/2018
Application: Apoptosis assay

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Anonymous on 09/18/2018
Application: Enzymatic activity in vitro

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Anonymous on 01/10/2018
Application: Characterization prior to use.

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By yoon kim on 12/01/2017
Application: Immunoassay Standard

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Konrad Gabrusiewicz on 10/20/2017
Application: CellProlif
Reason for Rating: We used HER2 protein for HER2-CAR T cells activation. It worked pretty well in the high concentration.

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Anonymous on 05/18/2016
Application: Binding assay/Protein-protein interaction
Reason for Rating: signal is strong, background is low

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF
By Anonymous on 10/26/2015
Application: ELISA Control Sample Tested: Human recombinant antibody Species: Human

Used as a control for Human ErbB2/Her2 Antibody (catalog number MAB1129).